SSc- Standard of Care, 2022

Daniel E Furst MD Professor of Rheumatology University of California in Los Angeles University of Washington University of Florence

Disclosures

- Abbvie
- Amgen
- Galderma
- Galapagos

- Horizon
- NIH
- Novartis
- Pfizer
- Prometheus

Treatment for Selected Aspects of SSc

- Interstitial Lung Disease
- Cardiac
- Severe Raynaud's +/- Gangrene

CASE STUDY 1

- A 45 y/o woman with scleroderma:
 - rapidly progressive skin thickening over the past year,
 - new onset dry cough, SOB after 1 flight of stairs and fatigue.
 - PFTs show FVC 85% and DLCO 60%
 - HRCT shows fibrosis and some "ground glass"

ground glass

Hazy parenchymal opacification even in presence of architectural distortion or reticular interstitial thickening


Patient 1

 The patient was placed on mycophenolate(MMF) 3 gm qd for 6 months but her skin worsened and her FVC decreased by 15 % predicted altho DLCO remained stable

• She had marked heartburn from the MMF, requiring both omeprazole and ranitidine

A few words about Mycophenolate Mofetil, as a reminder


Absolute change in % pred FVC by treatment arm (all observed data, ITT)




Mean skin fibrosis score (mRSS) results by treatment assignment

	CYC		MMF		
	Ν	Mean score ± SD	Ν	Mean score ± SD	
Baseline	73	14.0±10.6	69	14.3±10.4	
6 months	58	11.9±10.3	60	14.4±10.3	
12 months	55	9.5±7.9	58	12.4±9.2	
18 months	47	9.9±7.8	50	12.0±8.9	
24 months	53	7.9±7.4	53	11.4±9.2	

Kaplan-Meier Survival Plots* No. of subjects at risk & 95% Hall-Wellner bands



Adverse Events by Treatment Arm




*P<0.05, Fisher's Exact Test based on # of participants with each type of AE

What do you do next?

- Cyclophosphamide
- Tocilizumab
- Abatacept
- Rituximab
- Stem cell transplant

Cyclophosphamide

Predicting Response to CYC from the SLS1 study MRoth,CH Tseng,PJClement,DEFurst et al, ATS,2011



Skin Scores - 12-month*


Significant differences in mean adjusted skin scores in favor of CYC:

-3.06 [95% C.I.: -5.84, -0.28] (p=0.03)

*Covariance analysis; baseline score used as covariate; analysis confined to those with diffuse disease (N = 80)

Transitional Dyspnea Index

Magnitude of Effort @ 12 months




Summary and Conclusions

- A significant but modest effect on FVC (% predicted)
- A modest but real effect on the skin
- A real effect on dyspnea


Tocilizumab

Change From Baseline in mRSS at Week 24 (Primary Endpoint) and Week 48 (Secondary Endpoint)



Negative change indicates improvement. Means and 95% CI are from the repeated measures model.

Cumulative distribution of patients by absolute change in %predicted FVC from baseline to week 48




Imputed data in faSScinate study (week 48)

Khanna D, Denton CP...Furst DE. Lancet. 2016.387:2630-2640

		TCZ group Mean (SD) N=43	PBO group Mean (SD) N=40	P-value*
	mRSS, 0-51*	-5.26 (7.18)	-3.0 (5.76)	0.12
	FVC% predicted	-2.21 (2.33)	-6.50 (3.48)	<0.00001
48 Weeks asse	HAQ-DI, 0-3*	0.15 (0.69)	0.23 (0.50)	0.53
	Patient global assessment, 0-10*	-0.85 (2.22)	-0.36 (2.26)	0.33
	Physician global assessment, 0-10*	-3.18 (2.62)	-1.88 (2.74)	0.03

*Negative is improvement

CRISS scores at 48 weeks (using MCID of CRISS:>0.60)



prob of success

Khanna D, Denton CP...FurstDE. Lancet 2016. 387:2630-2640.


Overall Adverse Event Summary at Week 48


	PBO 162 mg qw SC n = 44	TCZ 162 mg qw SC n = 43
n (%)	BL to week 48	BL to week 48
Total patients with ≥1 AE	40 (90.9)	42 (97.7)
Total patients with ≥1 infectious AEs	22 (50.0)	24 (55.8)
Total patients with ≥1 SAE	15 (34.1)	14 (32.6)
Total patients with ≥1 infection SAE	2 (4.5)	7 (16.3)
Total patients with ≥1 noninfection SAE	14 (31.8)	10 (23.3)
Total patients who withdrew due to an AE	5 (11.4)	6 (14.0)
Deaths	1 (2.3)	3 (7.0)

• No anaphylaxis and no gastrointestinal perforation observed

- Deaths: PBO: heart failure (unrelated to study drug); TCZ: pulmonary infection (related), malignant arrhythmia (unrelated), multiorgan failure (unrelated)
- Serious infections: PBO: bone, skin and pulmonary infections; TCZ: bone, skin, pulmonary, and GI infections

Abatacept selectively modulates costimulation via CD80/86:CD28 pathway





ASSET- Abatacept vs Placebo in SSc- Secondary endpoints

	Diff from Placebo	
Pt Global	NS	
MD Global	<0.05	
FVC % ped	NS	
HAQ-DI	<0.05	
CRISS	0.03 at 6 months; 0.006 at 12 months	

Clinical Efficacy based on genetic signatures

p<0.001 vs plac.

Change in MRSS over tim Estimated change in MRSS over til Inflammatory ABA: . Inflammatory PLA Inflammatory ABA


Inflammatory PLA Normal-like ABA . . Normal-like PLA Normal-like ABA . Normal-like PLA toliferative ABA 🔸 Proliferative PLA Proliferative ABA 🔸 Proliferative PLA 6 10 -4 6 Time (in months) Time (in months) Change in FVC% Estimated change in FVC% 110 10 Time (in months) Time (in months) đ Change in HAQ-OI over time Estimated change in HAQ-DI 63 03 0.2 Change in HAQ-DI -0.1 0.1 0. ö 50 ġ 5 -0 0.3 10 Time (in months) Time (in months)

p=0.03 vs plac.

- n= 33(39%) with inflammatory signature
- n= 33(39%) with normal-like signature
- n=18(21%) with fibro-proliferative signature
- Did NOT separate for mRSS or FVC without separation into genetic signatures

RITUXIMAB


One Yr,Open,Controlled Trial of Rituximab for SSc- Results-Skin Daoussis D et al. Rheum,2009(epub,5/15/09)



24 week DB – RCT of rituximab for systemic sclerosis

Ebata S, Yoshizak A et al A&R 2021. 73(Suppl 10): abs 496


- N = 27/group
- rituximab 375 mg/M2 versus placebo weekly times 4 weeks.
- <u>Outcomes:</u>
- MR SS.
- Change percent predicted FVC




Conclusion: first actual CONTROLLED trial showing that rituximab works in SSC

Stem Cell Transplantation

- Autologous (self) purified stem cells infused after high dose immune suppression
- Goal: Reset the immune system^{1,2}



Improvement in mRSS and mHAQ after SCT for SSc(n=19)




Resolution of Dermal Fibrosis: Pt 11 Skin Biopsy


<u>**A+B :**</u> Pre-HCT: *grade 5*; *low + high* power

<u>**C+D**</u>: 1 year post-HCT: grade 2-3; low + high power

<u>E+F:</u> 5 years post-HCT: *grade 0*; *low* + *high* power



Kaplan-Meier Survival Estimates: (Treated Population)



Abbreviations: EFS, Event-free Survival; PP, Per Protocol (Treated) Population

What do you do next?

- Cyclophosphamide
- Tocilizumab
- Abatacept
- Rituximab
- Stem cell transplant

Patient-Jennifer

- 35 yr. old female with a 2 year history of exertional dyspnea
- Presently raising 3 children and performing daily activities
- Short of breath when climbing 1 flight of stairs or an incline
- Physical Exam: distant heart sounds; 2+ lower calf edema

Social History

No history of smoking, alcohol abuse, recreational drug use, or anorexigens

Labs:

FVC: 62%pred; DLCO: 55% predicted TLC:84% predicted EKG: low voltage, occasional PVC Chest CT

- No signs of interstitial lung disease or pulmonary emboli
- Enlarged Heart


Serum creatinine: 0.70 mg/dl(ULN: 1.3)

Case #2

What is your diagnosis?

- Pulmonary Hypertension
- Interstitial Lung Disease
- Cardiomyopathy
- Renal Failure
- Myositis
- Fatigue from trying to care for the chlidren and working and caring for husband

Inflammation INPUT FROM CARDIAC MRI



Tzelepis et al, Arthritis Rheum 2007;56:3827-3836

Thanks to Marco Matucci-Cerenic and Silvia Bellando-Randon


What is your diagnosis?

- Pulmonary Hypertension
- Interstitial Lung Disease
- Cardiomyopathy
- Renal Failure
- Myositis
- Fatigue from trying to care for the chlidren and working and caring for husband


Cardiac MRI detects diffuse fibrosis in SSc Poindron V, Chatelus E, et al. ARD. EULAR, 2017. OPO128. (page 106)

- N=72 SSc pts
 - Diffuse: 52%
 - Anti-Scl70: 40.3%
 - RNAP3: 8.3%
- Cardiac MRI -1.5T and gadolinium enhancement and echo
- Normal echo: 50% of the 36 diffuse myocardial fibrous by MRI

Conclusion: Diffuse myocardial fibrosis in 50% of pts and in 50% with normal echo (ie; fibrosis can occur with normal echo) % of 72 pts who underwent Cardiac MRI




Cardiac involvement in systemic sclerosis (SSc) has high prognostic relevance.



Clements PJ...Furst DE et al. *Arthritis Rheum* 1991. Ferri C et al. *Medicine* 2002.

EUSTAR database: 234 deaths including 128 SSc-related




Tyndall et al, Ann Rheum Dis 2010;69:1809-1815

Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy

Mueller KA et al . PlosOne May 12

If clinical signs of cardiac with mildly impaired LVEF.prognosis was poor with 28% MI within 22.5 months FU and associated with the degree of cardiac inflammation and fibrosis.



two arterioles with fibrosis and inflammation in the vessels Immunohistological staining with SM-actin : hyperplasia of smooth muscle in the vessel Thanks to Marco Matucci-Cerenic and Silvia Bellando-Randon

What do you do next?


- Observe
- Diuretic
- Cardiotonic
- Steroids
- Pacemaker
- Beta-blocker
- Anti-Arrhythmic


Patient #2- Jennifer

- She was given Furosemide 40 mg qod plus digoxin 0.125 mg qd and she felt better. Her mild edema disappeared and she could now climb 2 flights of stairs. Her energy improved.
- 3 months later, she comes in complaining of recurrent dizziness, lasting seconds occurring 2-5 times daily and fainting when she got up this morning. On exam, she has multiple PVCs.
- Holter monitor confirms multiple PVCs with one triplet and one 5 beat run of VT.

What do you do next?

- Observe
- Steroids
- Pacemaker
- Beta-blocker
- Anti-Arrhythmic






What do you do next?

- Observe
- Diuretic
- Cardiotonic
- Steroids
- Pacemaker
- Beta-blocker
- Anti-Arrythmic


SUMMARY

- Observe
- Diuretic
- Cardiotonic
- Steroids
- Pacemaker
- Beta-blocker
- Anti-Arrythmic

Raynaud's Phenomenon





Renal Angiogram



Mrs. Johnson

- 43 yr old with SSc for 4 yrs characterized by Raynaud's 5-10 x daily, ILD(FVC:65%; DLCO: 58%),mild ground glass on HRCT, mild dysphagia to meat and tenderness of wrists, PIP, knees. She is on Mycophenolate mofetil 2 gm daily and Aspirin 325 mg daily.
- She used nifedipine 90 mg qd but it didn't improve her Raynaud's
- She then used Losartan 25 mg qd with edema so it had to be stopped
- Sildenafil caused orthostasis despite using only 20 mg qd






Muscularis(muscle):

Calcium Channel Blockers Phosphodiesterase

- Endothelium

(inner layer):

Prostacyclin Endothelin-1 Hyperbaric Oxygen Nitroglycerin




Muscularis(muscle):

Calcium Channel Blockers Phosphodiesterase

-Endothelium

(inner layer):

Prostacyclin Endothelin-1 Hyperbaric Oxygen Nitroglycerin



Muscularis(muscle):


Calcium Channel Blockers Phosphodiesterase


-Endothelium

(inner layer):

Prostacyclin Endothelin-1 Hyperbaric Oxygen Nitrogylycerin


IV Iloprost for SSc Raynaud's 7-9 wk Results (p<0.05 for >50% ,NS for new) Wigley FM et al, AnnInt Med 1994,120:199





Hyperbaric Oxygen Treatment(HBOT) for Severe DU Armstrong S, Evans A et al JSRD. 2018. 3:185 (P247)

- 36 HBOT treated ulcers among 2261 pts in a Toronto cohort(1.6%)
- 30-50 treatments per pt,
 2.5 atmos., 5 days/wk
- 13 not fully treated
 - ("not healable"-no increased O2 in the lesion,2; technical,4; Anxiety,1)
 - AE: ear pain,2;Nausea,2



64% improved

14 day,Double-blind, cross-over study of Nitroglycerin(0.2 mg/hr) in Raynaud' s

- N=21 primary Raynaud's Disease and 21 SSc patients
- 7 days of Patches(NTG vs Placebo) applied to the chest wall
- Then 7 days of cross-over

	Comparison of NTG	vs Placebo
# Raynaud' s attacks/wk	<u>Raynaud' s</u> 0.002	<u>SSc</u> 0.01
Numbness	0.002	0.009
Pain	0.004	0.034
Severity	0.002	0.036

• NTG Improved: # attacks /wk, Numbness,

• Pain, Severity

Teh LS et al BrJRheum 1995;34:636

DB RCT of topical NTG in Raynaud's

Seibold JR, Khanna D, et al. JSRD 2018. 3:227-228

- N= 65 with 32 SSc Crest?
- DB X-over, single dose
- 16 minute trial

Conclusion: no effect in a single dose study. Table 1: Change from Baseline in PeakMain Raynaud's Symptom (MRS) Score atVisits 5 & 6 (Primary Endpoint)


		Тх
Top. NTG	Vehicle	Difference
65	65	
-20.19	-18.63	-1.56
mm	mm	mm
0.55		
78mm		
	65 -20.19 mm	65 65 -20.19 -18.63 mm mm 0.55

Mrs Johnson(2)

- Bosentan helps her Raynaud's by 60% but is expensive.
- She wants to stop her medications.

Mrs. Johnson (3)

- During summer, she stopped her Raynaud's medications but ulcers of the 2 and 3 finger tips developed and this interfered with sleep because they were so painful(8/10 pain VAS). On exam, the 2nd finger tip ulcer is infected. It is treated with local therapy and antibiotics and oxycodone
- What do you suggest?
 - IV Iloprost
 - Biofeedback
 - Sympathectomy of the palmar arch
 - Botoxin injections
 - Amputation of the finger distal phalanx



Muscularis(muscle):


Calcium Channel Blockers Phosphodiesterase

- Endothelium

(inner layer):

Prostacyclin Endothelin-1 Hyperbaric Oxygen Increased Nitric Oxide

Prazosin(4 mg/d) for Raynaud's-Episodes / 2 wks(P<0.05) Russell IJ J Rheum 1985;12:94



Prazosin (Minipress)-alpha 1 blockade

Losartan 50 mg vs Nifedipine 40mg of Raynaud's

Dziadzio M, Denton C P et al A&R 1999. 42; 2646-2655

N= 25 primary Raynaud'sand 25 SSc-related Raynaud's

15 week, open, randomized, controlled trial

Both groups improved—Primary > SSc(data not shown)

Reduced VCAM-1 and procollagen type1N-terminal propeptide if symptoms improved




Figure 3. Effect of losartan and nifedipine on the severity of episodes of Raynaud's phenomenon. The severity score was normalized to 100% at baseline. Bars show the mean and 1 SEM. P values determined by unpaired *t*-test. NS = not significant.





Figure 4. Effect of losartan and nifedipine on the frequency of episodes of Raynaud's phenomenon. The severity score was normalized to 100% at baseline. Bars show the mean and 1 SEM. *P* values determined by unpaired *t*-test.

Conclusion: Losartan worked better than nifedipine-MAJOR flaw: too low dose nifedipine

Biofeedback Training for SSc-Related Raynaud's Results (8/gp)


Freedman RR et al J Behavioral Med 1984;7:343



Biofeedback for SSc-Raynaud's

Sporbeek B et al. Rheum Intern. 2012.32:1469-73

- 3x/wk open, randomized controlled 4 wk study
- N= 10 Oscillation (swinging), 8 Temp.
 biofeedback; 10
 waiting control)





Conclusion: very few pts, open but randomized, controlled---biofeedback worked

Pilot DB-RCT of Botox for Raynaud's Phenomenon in SSc



1 hand injected with Botox 20 units; other hand injected with saline Caveat: ? Systemic effect from doses in 1 hand??






Conclusion: Botox had no effect

Partly double-blind, RCT dosing study of Botox B in SSc – Raynaud's Phenomenon

Motegi S-I, Liehara A et al Acta Dremat Vener 2017. 97: 843-850

- N= 8-10/gp
- No Rx or 250,1000,2000 units Botox B
- Dosing blinded but "no rx" gp open



Conclusion: Despite flawed design, presence of blinded dose effect strongly favors efficacy of Botox B

Mrs. Johnson (4)

• 2 months later, the ulcers are worse despite Iloprost and biofeedback and there is gangrene of the 2nd, 3rd and 4th finger tips



Mrs. Johnson (3)

- What do you suggest?
 - Sympathectomy of the palmar arch
 - Amputation of the finger distal phalanx

Pulse Pressure in Digital Artery after Adventitial Stripping(N=5) B Balogh et al J Hand Surg 2002; 27A:1073

BEFORE




AFTER

Peri-arterial Sympathectomy for Refractory Digital Ischemia in SSc

NJ Sweiss et al abs 1437 ACR 2003

- Very Short Follow-up- only 4.6 months
- 129 fingers among 38 pts
- 81% healed within 2.3 months
- (range: 0.3-83 months)
- 5/129(4%) did not heal

Mrs Johnson



Adventitia (Outer layer): Surgery

Muscularis(muscle):

Calcium Channel Blockers Phosphodiesterase


Endothelium

(inner layer):

Prostacyclin

Endothelin-1 Hyperbaric Oxygen Increased Nitric Oxide

SUMMARY



Adventitia (Outer layer): Surgery

Muscularis(muscle):

Calcium Channel Blockers Phosphodiesterase


Endothelium

(inner layer):

Prostacyclin Endothelin-1 Hyperbaric Oxygen Increased Nitric Oxide

Treatment for Selected Aspects of SSc

- Interstitial Lung Disease
- Cardiac
- Severe Raynaud's +/- Gangrene



Thank you for your attention